Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Trista J. Stankowski-Drengler"'
Autor:
James E. Haine, Trista J. Stankowski-Drengler, Jennifer L. Tucholka, Jessica R. Schumacher, Catherine R. Breuer, Courtney Maxcy, Heather B. Neuman, Maureen A. Smith, Kristine L. Kwekkeboom, Amye J. Tevaarwerk
Publikováno v:
Cancer Research. 81:PS9-25
Introduction: Prior studies have demonstrated that breast cancer survivors are less likely to receive primary care preventive services than non-cancer patients. However, even recent studies have largely assessed survivors diagnosed over a decade ago.
Autor:
Heather B. Neuman, Bret Hanlon, Mary E Hitchcock, Devon Livingston-Rosanoff, Trista J. Stankowski-Drengler, Jessica R. Schumacher
Publikováno v:
J Surg Res
Background Trials demonstrate equivalent survival for breast cancers treated with neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (AC). However, these were conducted before the recognition of the importance of receptor subtype for survival an
Autor:
Jordan G. Bruce, Trista J. Stankowski-Drengler, Jennifer L. Tucholka, Caprice C. Greenberg, Jennifer G. Steiman, Bret Hanlon, Heather B. Neuman, Lee G. Wilke, Jessica R. Schumacher, Nicole M. Steffens
Publikováno v:
Ann Surg Oncol
Patient participation in treatment decision-making is a health care priority. This study hypothesized that providing a decision aid before surgical consultation would better prepare patients for decision-making. The objective was to examine the impac
Autor:
Jessica R. Schumacher, Alyssa A. Wiener, Samuel O. Poore, Caprice C. Greenberg, Amanda B. Francescatti, Christina M. Dudley, Heather B. Neuman, Trista J. Stankowski-Drengler
Publikováno v:
Clin Breast Cancer
BACKGROUND AND OBJECTIVES: Some surgeons remain hesitant to perform immediate breast reconstruction (IBR) in patients with higher risk cancers due to concerns about cancer recurrence and/or detection. Our objective was to determine the rate of ipsila
Publikováno v:
Curr Treat Options Oncol
As the use of neoadjuvant systemic therapy (NAST) increases, the optimal management of the axilla has become increasingly complex. Consensus among professional organizations is that those patients with clinically negative axillary nodes who are being
Autor:
Ya-Huei Li, Jessica M. Engel, Trista J. Stankowski-Drengler, Adedayo A. Onitilo, Oyewale Shiyanbola, Seth O. Fagbemi, Sabo Tanimu
Publikováno v:
Clin Med Res
Objective: Perioperative chemotherapy can potentially downstage esophageal cancer, reducing the risk of early systemic dissemination. One recommended neoadjuvant regimen for managing gastroesophageal junction and esophageal cancer is docetaxel, cispl
Autor:
Caprice C. Greenberg, Jennifer L. Tucholka, Jessica R. Schumacher, Samuel O. Poore, Trista J. Stankowski-Drengler, Heather B. Neuman, Lee G. Wilke
Publikováno v:
Breast J
Publikováno v:
Surgical Oncology Clinics of North America. 27:653-663
The goal of cancer care delivery research (CCDR) is to inform sustainable practice changes that will provide better clinical outcomes and patient experience guided by patient values. CCDR encompasses salient concepts from other well-established resea
Autor:
Caprice C. Greenberg, Bret Hanlon, Nicholas Marka, Devon Livingston-Rosanoff, Trista J. Stankowski-Drengler, Kara Vande Walle, Heather B. Neuman, Jessica R. Schumacher, Lee G. Wilke
Publikováno v:
Breast J
Delays in the initiation of adjuvant chemotherapy or radiation therapy are associated with worse outcomes in patients undergoing treatment for breast cancer. However, the impact of the time to initiation of neo-adjuvant chemotherapy (NAC) on patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbdbca41747646758119baeca2559c8c
https://europepmc.org/articles/PMC7723063/
https://europepmc.org/articles/PMC7723063/
Autor:
Heather B. Neuman, Bret Hanlon, Devon Livingston-Rosanoff, Jessica R. Schumacher, Caprice C. Greenberg, Trista J. Stankowski-Drengler, K. Van de Walle, Lee G. Wilke
Publikováno v:
Ann Surg Oncol
Pathologic complete response (pCR) after neoadjuvant chemotherapy has a demonstrated survival advantage; however, outcomes for non-pCR by receptor status are less understood. We sought to evaluate survival and distant recurrence by receptor status fo